Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (515)	3/15/2006 6:03:26 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

Introgen Therapeutics, Inc. (ticker: ingn, exchange: NASDAQ Stock Exchange (.O)) News Release - 3/15/06 Introgen Therapeutics Reports Fourth Quarter 2005 Financial Results; Results in Line With Expectations. AUSTIN, Texas, March 15 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN) announced today its results for the quarter and year ended December 31, 2005, reporting progress during the period in its research and development and clinical trial programs. During the quarter ended December 31, 2005 Introgen used cash, cash equivalents and short-term investments of $5.1 million to conduct its operations. Introgen's cash, cash equivalents, marketable securities and short-term investments were $36.0 million at December 31, 2005. Revenue was $624,000 for the quarter ended December 31, 2005, compared to revenue of $398,000 for the quarter ended September 30, 2005 and $1.2 million for the quarter ended December 31, 2004. Operating expense was $7.7 million for the quarter ended December 31, 2005, compared to $6.7 million for the quarter ended September 30, 2005 and $5.8 million for the quarter ended December 31, 2004. Introgen reported a net loss of $6.7 million, or $0.19 per share, for the quarter ended December 31, 2005. These results compare to a net loss of $6.1 million, or $0.18 per share, for the previous quarter ended September 30, 2005 and a net loss of $4.4 million, or $0.16 per share, for the comparable quarter ended December 31, 2004. For the year ended December 31, 2005, Introgen reported a net loss of $26.1 million, or $0.80 per share, compared to a net loss of $24.4 million, or $0.91 per share for the year ended December 31, 2004. Revenue for the year ended December 31, 2005 was $1.9 million, compared to revenue of $1.8 million for the year ended December 31, 2004. Operating expense was $29.2 million for the year ended December 31, 2005 compared to $27.1 million for the year ended December 31, 2004. Quarterly Conference Call Introgen has scheduled a conference call to discuss the financial results at 4:30 p.m. Eastern Standard Time today. Interested parties can access a live Internet broadcast at introgen.com . The call may also be accessed by dialing 1-877-616-4476 or 1-706-679-7372. For those unable to listen to the broadcast the call will be archived at Introgen's website in the Investor Relations section.